{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T06:32:09Z","timestamp":1788503529610,"version":"build-2803163510"},"reference-count":42,"publisher":"Elsevier BV","issue":"43","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.vaccine.2019.08.077","type":"journal-article","created":{"date-parts":[[2019,9,9]],"date-time":"2019-09-09T07:38:07Z","timestamp":1568014687000},"page":"6470-6477","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Intranasal nanoemulsion-adjuvanted HSV-2 subunit vaccine is effective as a prophylactic and therapeutic vaccine using the guinea pig model of genital herpes"],"prefix":"10.1016","volume":"37","author":[{"given":"David I.","family":"Bernstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhonda D.","family":"Cardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando J.","family":"Bravo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek","family":"Hamouda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek A.","family":"Pullum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vira","family":"Bitko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Fattom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.08.077_b0005","unstructured":"Centers for Disease C, Prevention. Seroprevalence of herpes simplex virus type 2 among persons aged 14-49 years \u2013 United States, 2005\u20132008. MMWR Morb Mortal Wkly Rep. 2010;59(15):456\u20139. Epub 2010\/04\/24. PubMed PMID: 20414188."},{"key":"10.1016\/j.vaccine.2019.08.077_b0010","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1146\/annurev.med.59.061606.095540","article-title":"Herpes simplex: insights on pathogenesis and possible vaccines","volume":"59","author":"Koelle","year":"2008","journal-title":"Annu Rev Med"},{"issue":"9605","key":"10.1016\/j.vaccine.2019.08.077_b0015","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1016\/S0140-6736(07)61908-4","article-title":"Genital herpes","volume":"370","author":"Gupta","year":"2007","journal-title":"Lancet"},{"issue":"9267","key":"10.1016\/j.vaccine.2019.08.077_b0020","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/S0140-6736(00)04638-9","article-title":"Herpes simplex virus infections","volume":"357","author":"Whitley","year":"2001","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.vaccine.2019.08.077_b0025","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/ije\/26.4.698","article-title":"Genital herpes infection: a review","volume":"26","author":"Brugha","year":"1997","journal-title":"Int J Epidemiol"},{"issue":"14","key":"10.1016\/j.vaccine.2019.08.077_b0030","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1001\/jama.2011.420","article-title":"Genital shedding of herpes simplex virus among symptomatic and asymptomatic persons with HSV-2 infection","volume":"305","author":"Tronstein","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2019.08.077_b0035","doi-asserted-by":"crossref","unstructured":"Schiffer JT, Abu-Raddad L, Mark KE, Zhu J, Selke S, Magaret A, et al. Frequent release of low amounts of herpes simplex virus from neurons: results of a mathematical model. Sci Transl Med. 2009;1(7):7ra16. Epub 2010\/02\/18. doi: 10.1126\/scitranslmed.3000193. PubMed PMID: 20161655; PubMed Central PMCID: PMCPMC2818652.","DOI":"10.1126\/scitranslmed.3000193"},{"issue":"1","key":"10.1016\/j.vaccine.2019.08.077_b0040","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/QCO.0000000000000029","article-title":"Current thinking on genital herpes","volume":"27","author":"Hofstetter","year":"2014","journal-title":"Curr Opin Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2019.08.077_b0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0114989","article-title":"Global estimates of prevalent and incident herpes simplex virus type 2 infections in 2012","volume":"10","author":"Looker","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2019.08.077_b0050","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/978-1-4419-7185-2_15","article-title":"Neonatal herpes simplex virus infections: where are we now?","volume":"697","author":"Thompson","year":"2011","journal-title":"Adv Exp Med Biol"},{"issue":"1","key":"10.1016\/j.vaccine.2019.08.077_b0055","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/01.aids.0000198081.09337.a7","article-title":"Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies","volume":"20","author":"Freeman","year":"2006","journal-title":"AIDS"},{"issue":"14","key":"10.1016\/j.vaccine.2019.08.077_b0060","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1097\/QAD.0b013e32832efdf1","article-title":"Foreskin inflammation is associated with HIV and herpes simplex virus type-2 infections in Rakai, Uganda","volume":"23","author":"Johnson","year":"2009","journal-title":"AIDS"},{"issue":"5","key":"10.1016\/j.vaccine.2019.08.077_b0065","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/QAD.0b013e328012b896","article-title":"Negative mucosal synergy between Herpes simplex type 2 and HIV in the female genital tract","volume":"21","author":"Rebbapragada","year":"2007","journal-title":"AIDS"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2019.08.077_b0070","doi-asserted-by":"crossref","first-page":"i17","DOI":"10.1136\/sti.2006.023549","article-title":"Proportion of new HIV infections attributable to herpes simplex 2 increases over time: simulations of the changing role of sexually transmitted infections in sub-Saharan African HIV epidemics","volume":"83","author":"Freeman","year":"2007","journal-title":"Sex Transm Infect"},{"issue":"9","key":"10.1016\/j.vaccine.2019.08.077_b0075","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1097\/QAD.0000000000000646","article-title":"Changes in the contribution of genital tract infections to HIV acquisition among Kenyan high-risk women from 1993 to 2012","volume":"29","author":"Masese","year":"2015","journal-title":"AIDS"},{"issue":"3","key":"10.1016\/j.vaccine.2019.08.077_b0080","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/OLQ.0b013e318285c6d2","article-title":"The estimated direct medical cost of selected sexually transmitted infections in the United States, 2008","volume":"40","author":"Owusu-Edusei","year":"2013","journal-title":"Sex Transm Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2019.08.077_b0085","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa1103151","article-title":"Efficacy results of a trial of a herpes simplex vaccine","volume":"366","author":"Belshe","year":"2012","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.vaccine.2019.08.077_b0090","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1016\/j.vaccine.2015.12.076","article-title":"Status of vaccine research and development of vaccines for herpes simplex virus","volume":"34","author":"Johnston","year":"2016","journal-title":"Vaccine"},{"issue":"7424","key":"10.1016\/j.vaccine.2019.08.077_b0095","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nature11522","article-title":"A vaccine strategy that protects against genital herpes by establishing local memory T cells","volume":"491","author":"Shin","year":"2012","journal-title":"Nature"},{"issue":"7450","key":"10.1016\/j.vaccine.2019.08.077_b0100","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/nature12110","article-title":"Immune surveillance by CD8\u221d\u221d+ skin-resident T cells in human herpes virus infection","volume":"497","author":"Zhu","year":"2013","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.vaccine.2019.08.077_b0105","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1002\/eji.201142346","article-title":"Nanoemulsion mucosal adjuvant uniquely activates cytokine production by nasal ciliated epithelium and induces dendritic cell trafficking","volume":"42","author":"Makidon","year":"2012","journal-title":"Eur J Immunol"},{"issue":"3","key":"10.1016\/j.vaccine.2019.08.077_b0110","doi-asserted-by":"crossref","first-page":"615","DOI":"10.4161\/hv.27383","article-title":"Intranasal immunization with W 80 5EC adjuvanted recombinant RSV rF-ptn enhances clearance of respiratory syncytial virus in a mouse model","volume":"10","author":"Passmore","year":"2014","journal-title":"Hum Vaccin Immunother"},{"issue":"8","key":"10.1016\/j.vaccine.2019.08.077_b0115","doi-asserted-by":"crossref","first-page":"e2954","DOI":"10.1371\/journal.pone.0002954","article-title":"Pre-clinical evaluation of a novel nanoemulsion-based hepatitis B mucosal vaccine","volume":"3","author":"Makidon","year":"2008","journal-title":"PLoS ONE"},{"issue":"8","key":"10.1016\/j.vaccine.2019.08.077_b0120","doi-asserted-by":"crossref","first-page":"4020","DOI":"10.1128\/IAI.00070-07","article-title":"Mucosal immunization with a novel nanoemulsion-based recombinant anthrax protective antigen vaccine protects against Bacillus anthracis spore challenge","volume":"75","author":"Bielinska","year":"2007","journal-title":"Infect Immun"},{"issue":"2","key":"10.1016\/j.vaccine.2019.08.077_b0125","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1128\/CVI.00440-07","article-title":"A novel, killed-virus nasal vaccinia virus vaccine","volume":"15","author":"Bielinska","year":"2008","journal-title":"Clin Vaccine Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2019.08.077_b0130","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1089\/aid.2007.0148","article-title":"Nasal immunization with a recombinant HIV gp120 and nanoemulsion adjuvant produces Th1 polarized responses and neutralizing antibodies to primary HIV type 1 isolates","volume":"24","author":"Bielinska","year":"2008","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"25\u201326","key":"10.1016\/j.vaccine.2019.08.077_b0135","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1016\/S0264-410X(03)00381-5","article-title":"Development of immune response that protects mice from viral pneumonitis after a single intranasal immunization with influenza A virus and nanoemulsion","volume":"21","author":"Myc","year":"2003","journal-title":"Vaccine."},{"issue":"6","key":"10.1016\/j.vaccine.2019.08.077_b0140","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.4049\/jimmunol.1301424","article-title":"Distinct pathways of humoral and cellular immunity induced with the mucosal administration of a nanoemulsion adjuvant","volume":"192","author":"Bielinska","year":"2014","journal-title":"J Immunol"},{"issue":"7","key":"10.1016\/j.vaccine.2019.08.077_b0145","doi-asserted-by":"crossref","first-page":"e21823","DOI":"10.1371\/journal.pone.0021823","article-title":"A novel inactivated intranasal respiratory syncytial virus vaccine promotes viral clearance without Th2 associated vaccine-enhanced disease","volume":"6","author":"Lindell","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2019.08.077_b0150","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.micpath.2012.11.001","article-title":"HSV-2 vaccine: current state and insights into development of a vaccine that targets genital mucosal protection","volume":"58","author":"Roth","year":"2013","journal-title":"Microb Pathog"},{"issue":"Suppl 5","key":"10.1016\/j.vaccine.2019.08.077_b0155","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1469-0691.2012.03995.x","article-title":"B cell and T cell immunity in the female genital tract: potential of distinct mucosal routes of vaccination and role of tissue-associated dendritic cells and natural killer cells","volume":"18","author":"Anjuere","year":"2012","journal-title":"Clin Microbiol Infect"},{"issue":"6241","key":"10.1016\/j.vaccine.2019.08.077_b0160","doi-asserted-by":"crossref","first-page":"aaa8205","DOI":"10.1126\/science.aaa8205","article-title":"A mucosal vaccine against Chlamydia trachomatis generates two waves of protective memory T cells","volume":"348","author":"Stary","year":"2015","journal-title":"Science"},{"issue":"4 Suppl","key":"10.1016\/j.vaccine.2019.08.077_b0165","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1038\/nm1213","article-title":"Mucosal immunity and vaccines","volume":"11","author":"Holmgren","year":"2005","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.vaccine.2019.08.077_b0170","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1128\/AAC.44.9.2471-2474.2000","article-title":"Dendrimers, a new class of candidate topical microbicides with activity against herpes simplex virus infection","volume":"44","author":"Bourne","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.1016\/j.vaccine.2019.08.077_b0175","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02257-16","article-title":"Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir","volume":"91","author":"Hensel","year":"2017","journal-title":"J Virol"},{"issue":"11","key":"10.1016\/j.vaccine.2019.08.077_b0180","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1016\/j.vaccine.2011.01.005","article-title":"Effects of herpes simplex virus type 2 glycoprotein vaccines and CLDC adjuvant on genital herpes infection in the guinea pig","volume":"29","author":"Bernstein","year":"2011","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2019.08.077_b0185","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1093\/infdis\/155.5.914","article-title":"Vaccination with recombinant herpes simplex virus glycoproteins: protection against initial and recurrent genital herpes","volume":"155","author":"Stanberry","year":"1987","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2019.08.077_b0190","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3851\/IMP2499","article-title":"Topical SMIP-7.7, a toll-like receptor 7 agonist, protects against genital herpes simplex virus type-2 disease in the guinea pig model of genital herpes","volume":"23","author":"Bernstein","year":"2014","journal-title":"Antivir Chem Chemother"},{"issue":"21","key":"10.1016\/j.vaccine.2019.08.077_b0195","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1016\/j.vaccine.2009.10.025","article-title":"The adjuvant CLDC increases protection of a herpes simplex type 2 glycoprotein D vaccine in guinea pigs","volume":"28","author":"Bernstein","year":"2010","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2019.08.077_b0200","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.vaccine.2018.11.042","article-title":"The HSV-1 live attenuated VC2 vaccine provides protection against HSV-2 genital infection in the guinea pig model of genital herpes","volume":"37","author":"Bernstein","year":"2019","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2019.08.077_b0205","first-page":"331","article-title":"Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials","volume":"282","author":"Corey","year":"1999","journal-title":"Chiron HSV Vaccine Study Group JAMA"},{"issue":"12","key":"10.1016\/j.vaccine.2019.08.077_b0210","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/j.vaccine.2019.02.002","article-title":"Recombinant H5 hemagglutinin adjuvanted with nanoemulsion protects ferrets against pathogenic avian influenza virus challenge","volume":"37","author":"Wang","year":"2019","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19311533?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19311533?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:37:03Z","timestamp":1759401423000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19311533"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":42,"journal-issue":{"issue":"43","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S0264410X19311533"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.08.077","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intranasal nanoemulsion-adjuvanted HSV-2 subunit vaccine is effective as a prophylactic and therapeutic vaccine using the guinea pig model of genital herpes","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.08.077","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}